(Q61866169)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23355128%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Cardiovascular risk in hypertension - can we ask for more? : focus on aliskiren (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23355128%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23355128%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

1 October 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23355128%20AND%20SRC:MED&resulttype=core&format=json

High Blood Pressure & Cardiovascular Prevention

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23355128%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23355128%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23355128%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

255-268

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23355128%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/0151642-200815040-00005

22 February 2020

exact match

0 references

cites work

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial

1 reference

12 December 2020

Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States

1 reference

12 December 2020

Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment

1 reference

12 December 2020

Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers

1 reference

12 December 2020

Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension

1 reference

12 December 2020

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

12 December 2020

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

12 December 2020

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

12 December 2020

Blood pressure control in Italy: results of recent surveys on hypertension

1 reference

12 December 2020

Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey.

1 reference

12 December 2020

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

1 reference

12 December 2020

Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus

1 reference

12 December 2020

Fewer mega-trials and more clinically oriented studies in hypertension research? The case of blocking the renin-angiotensin-aldosterone system

1 reference

12 December 2020

Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease?

1 reference

12 December 2020

Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I.

1 reference

12 December 2020

Blood pressure is insufficiently controlled in European patients with established coronary heart disease

1 reference

12 December 2020

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

12 December 2020

Aliskiren combined with losartan in type 2 diabetes and nephropathy

1 reference

12 December 2020

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

1 reference

12 December 2020

1 reference

12 December 2020

Telmisartan to prevent recurrent stroke and cardiovascular events

1 reference

12 December 2020

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

1 reference

12 December 2020

Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren

1 reference

12 December 2020

Aliskiren: a review of its use in the management of hypertension

1 reference

12 December 2020

Oral renin inhibitors

1 reference

12 December 2020

Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study

1 reference

12 December 2020

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

1 reference

12 December 2020

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

1 reference

12 December 2020

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

1 reference

12 December 2020

Development of heart failure in recent hypertension trials.

1 reference

12 December 2020

Direct Renin inhibition with aliskiren in obese patients with arterial hypertension

1 reference

12 December 2020

Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy

1 reference

12 December 2020

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

12 December 2020

Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA).

1 reference

12 December 2020

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

1 reference

12 December 2020

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

12 December 2020

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

1 reference

12 December 2020

Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys

1 reference

12 December 2020

Direct renin inhibition: an evaluation of the safety and tolerability of aliskiren

1 reference

12 December 2020

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

12 December 2020

Blood pressure parameters and risk of fatal stroke, NHANES II mortality study

1 reference

12 December 2020

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

1 reference

12 December 2020

Renin-angiotensin-aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke).

1 reference

12 December 2020

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

1 reference

12 December 2020

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

1 reference

12 December 2020

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

1 reference

12 December 2020

Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?

1 reference

12 December 2020

Renin, prorenin and the putative (pro)renin receptor

1 reference

12 December 2020

Early versus delayed enalapril in patients with left ventricular systolic dysfunction: impact on morbidity and mortality 15 years after the SOLVD trial

1 reference

12 December 2020

The (pro)renin receptor: pathophysiological roles in cardiovascular and renal pathology

1 reference

12 December 2020

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

1 reference

12 December 2020

2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension

1 reference

12 December 2020

Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects

1 reference

12 December 2020

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial

1 reference

12 December 2020

Long-term follow-up after tight control of blood pressure in type 2 diabetes.

1 reference

12 December 2020

Systolic and diastolic blood pressure control in antihypertensive drug trials

1 reference

12 December 2020

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

1 reference

12 December 2020

Essential hypertension

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of aliskiren

1 reference

12 December 2020

Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension

1 reference

12 December 2020

Aliskiren: renin inhibitor for hypertension management

1 reference

12 December 2020

Therapeutic implications of recent megatrials in hypertension: in favor of new drugs

1 reference

12 December 2020

The cardiovascular continuum and renin-angiotensin-aldosterone system blockade

1 reference

12 December 2020

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

12 December 2020

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

12 December 2020

Renin receptor blockade: a better strategy for renal protection than renin-angiotensin system inhibition?

1 reference

12 December 2020

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

1 reference

12 December 2020

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption

1 reference

12 December 2020

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

1 reference

12 December 2020

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

12 December 2020

Risk stratification in hypertension: new insights from the Framingham Study

1 reference

12 December 2020

The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions

1 reference

12 December 2020

Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension

1 reference

12 December 2020

Hypertension: uncontrolled and conquering the world

1 reference

12 December 2020

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

12 December 2020

The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease).

1 reference

12 December 2020

The development of the direct renin inhibitor aliskiren: treating hypertension and beyond

1 reference

12 December 2020

Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension

1 reference

12 December 2020

Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment

1 reference

12 December 2020

Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease

1 reference

12 December 2020

World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries

1 reference

12 December 2020